Efficacy of Sarafloxacin in Broilers after Experimental Infection with Escherichia coli

Infections of chickens with Escherichia coli serotypeO78 can be treated with the antibiotic sarafloxacin. Three experiments were conducted on the administration of this drug to chickens that had been experimentally infected with E. coli. The birds were monitored for 10 days after infection for their average daily gain (ADG) and feed conversion ratio (FCR), and the post-mortem pathology was assessed. In the first experiment, sarafloxacin (20 mg/L, equivalent to 5 mg/kg live weight per day), given in the drinking water for 3 days after infection, led to a reduction in the mortality from 75% to 27%, but the ADG of the treated birds was still less than that of the uninfected controls. In the second experiment, when the sarafloxacin was administered at the same dose in the water but over only 2 h, there was also a considerable reduction in mortality, and the ADG and the FCR also improved significantly. In the third experiment, the dose dependence of the drug was tested. The birds were given 5 and 10 mg/kg per day sarafloxacin in each group, starting within 2 h after infection. This rapid administration of the drug completely prevented mortality, while the ADG and FCR were similar to those of the uninfected controls.     

Development of a monoclonal antibody-based co-agglutination test to detect enterotoxigenic Escherichia coli isolated from diarrheic neonatal calves

Escherichia coli (E. coli) strains were collected from young diarrheic calves in farms and field. Strains that expressed the K99 (F5) antigen were identified by agglutination tests using reference antibodies to K99 antigen and electron microscopy. The K99 antigen from a selected field strain (SAR-14) was heat-extracted and fractionated on a Sepharose CL-4B column. Further purification was carried out by sodium deoxycholate treatment and/or ion-exchange chromatography. Monoclonal antibodies to purified K99 antigen were produced by the hybridoma technique, and a specific clone, NEK99-5.6.12, was selected for propagation in tissue culture. The antibodies, thus obtained, were affinity-purified, characterized and coated onto Giemsa-stained Cowan-I strain of Staphylococcus aureus (S. aureus). The antibody-coated S. aureus were used in a co-agglutination test to detect K99+ E. coli isolated from feces of diarrheic calves. The specificity of the test was validated against reference monoclonal antibodies used in co-agglutination tests, as well as in ELISA. Specificity of the monoclonal antibodies was also tested against various Gram negative bacteria. The developed antibodies specifically detected purified K99 antigen in immunoblots, as well as K99+ E. coli in ELISA and co-agglutination tests. The co-agglutination test was specific and convenient for large-scale screening of K99+ E. coli isolates.     

鸡致病性大肠杆菌1型菌毛fimI基因克隆与序列测定

对鸡O2血清型致病性大肠杆菌1型菌毛fimI基因进行了扩增并与国外同源菌株基因序列进行了比较。结果表明：两者核苷酸同源性达98．42％，预测氨基酸顺序同源性达98．92％。fimI基因的预测氨基酸序列中仅第46位氨基酸由ALA变为THR，第76位氨基酸由SER变为ALA，其余核苷酸的变化未影响氨基酸的翻译，推测，这种改变是由分离株的差异所引起的。     

猪轮状病毒Vp4全基因与乳酸菌非抗性表达载体的重组及在大肠杆菌中的表达

以猪A组轮状病毒mRNA为模板，应用优化的反转录聚合酶链式反应（RT—PCR）技术，扩增了2331 bp的Vp4全长基因，通过T-A克隆技术，将PCR产物克隆至克隆载体pGEM-T中，构建质粒pGEM-T-Vp4。以SalⅠ和KpnⅠ双酶切pGEM—T—Vp4．和以胸苷酸合成酶基因（thymidylate synthase，thyA）为选择压力的非抗生素抗性的穿梭表达载体pW425t，并将纯化的Vp4基因亚克隆至表达载体pW425t中，构建出可以在乳酸菌与大肠杆菌之间穿梭表达的原核表达重组质粒pW425t-Vp4。将pW425t-Vp4转化至thyA基因缺陷型的大肠杆菌感受态E．coli X13中，通过生长功能弥补筛选阳性克隆，SDS-PAGE分析，可见约87.67Ku融合蛋白。Western blot分析表明，该蛋白具有与轮状病毒多克隆抗体的反应原性，研究结果为pW425t-Vp4在乳酸菌受体菌株中表达提供科学依据。     

黄芩抗鸡大肠杆菌作用的研究

通过体外试验和体内试验两种方法研究了黄芩抗鸡大肠杆菌的作用。结果表明，黄芩水煎液对鸡大肠杆菌的最小体外抑菌浓度为2．5g／mL；当药物浓度为5g／mL时可使7日龄雏鸡获得90％以上的攻毒保护；药物浓度为10g／mL时可使100％雏鸡获得攻毒保护，说明黄芩可以对抗鸡大肠杆菌，用于防治鸡的大肠杆菌病。     

鸡大肠杆菌O78对喹诺酮类药物高耐药株的分子鉴定

就临床分离的鸡大肠杆菌O78对喹诺酮类药物的最低抑菌浓度（MIC）进行了测定，得到对喹诺酮类药物有不同耐药水平的细菌23株。根据GenBank已公布的QRDRs序列，设计了分剐扩增gyrA、gyrB、parC和parE基因的4对引物，以筛选的23株耐药菌DNA为模板，进行了PCR扩增。序列分析及AcrA的Western blotting检测结果表明，临床分离的鸡大肠杆菌对喹诺酮类药物的耐药水平与GyrA和ParC的突变密切相关，而AcrAB外输泵的表达水平无显著变化。提示临床分离的鸡大肠杆菌O78的耐药水平与喹诺酮类药物的选择性压力有关，它诱导了DNA旋转酶和拓扑异构酶IV的基因突变，可能不能激活AcrAB外输泵。     

我国南方猪高热病的研究(Ⅰ)——大肠杆菌的分离、鉴定和致病性测定

从湖南3个高热病发病猪场11头病死猪的病料组织中均分离出了大肠杆菌,经血清学鉴定,鞭毛抗原(K88、K99、987P和F41)全为阴性反应。经过157种菌体抗原血清学检测,血清型为5、6、15、22、32和83型。药物敏感试验结果表明,分离的大肠杆菌对大多数常用药物耐药,对氟喹诺酮和头孢类药物敏感。将其中4头猪原代分离的大肠菌培养物以原倍(2×107个/mL)、104和108稀释的菌液分别感染18~22 g小白鼠,原倍菌液感染的小白鼠12/30在感染后24 h内出现死亡,而104和108稀释菌液感染的小白鼠均健活;将未经除菌的病死猪组织悬液、过滤除菌的组织悬液、大肠杆菌、过滤除菌的组织悬液及大肠杆菌分别感染30日龄左右的健康小猪,除未经除菌的组织悬液感染猪3/3发病,2/3死亡外,其余所有感染猪只出现体温升高,升幅达1~2℃,减食,精神萎靡,但没有死亡;将死亡猪再次分离到的大肠杆菌感染小白鼠和猪,小白鼠12/15出现死亡,感染猪只出现体温升高(超过1℃),没有出现死亡。结果证明:大肠杆菌在高热病的发病过程中只起协同诱发作用,引起猪发病死亡的真正原因可能是病毒感染。     

4味中药及其与抗菌药的复方制剂的MIC测定

用改进的试管两倍稀释法测定了黄连、鱼腥草、大青叶和苦参4味中药及其相互配伍（1：1）对标准大肠杆菌的最小抑菌浓度和4味中药与抗菌药配伍（1000：1）对临床分离鸡大肠杆菌的最小抑菌浓度。结果表明，4味中药及其相互配伍对大肠杆菌标准株有一定的抑制作用，其MIC值介于3．91—62．50mg／mL之间，其中大青叶和鱼腥草以1：l配伍对大肠杆菌抑菌效果最好，MIC为3．91mg／mL；对临床分离株，单方药中黄连抑菌效果最好，MIC为31．25mg／mL，24种复方药中，黄连和盐酸多西环素或加替沙星以1000：1配伍的抑菌效果最好，其MIC为3．91mg／mL。     

苏太仔猪FUT1基因M307位点多态性与F18大肠杆菌抗病相关性的体外鉴定

采用PCR-RFLP方法检测了江苏苏太断奶仔猪FUT1基因M307位点等位基因多态性分布,在所检的49头仔猪中,GG基因型个体16头,AG基因型19头,AA基因型14头。在此基础上,制备上述不同基因型个体仔猪小肠上皮细胞,分别与表达F18ab菌毛的野生型大肠杆菌、表达F18ac菌毛含fed操纵子全基因的重组大肠杆菌和V型系统表面分泌表达F18abFedF亚单位的重组大肠杆菌进行体外黏附试验和黏附抑制试验。研究结果表明:FUT1基因M307位点中GG型和AG型仔猪小肠上皮细胞均能黏附上述3种大肠杆菌,而AA型个体小肠上皮细胞则不能黏附。将上述3种大肠杆菌分别与抗F18ab菌毛高免血清、F18ac菌毛高免血清及抗F18abFedF亚单位单因子血清作用后,则失去黏附仔猪肠上皮细胞能力。上述结果对苏太猪从体外试验上证明了FUT1基因M307位点多态性与断奶仔猪腹泻和水肿病存在着直接的相关性。     

大肠埃希菌不耐热肠毒素作为黏膜免疫佐剂的研究进展

免疫佐剂是一类通过刺激机体免疫系统而非特异性地增强机体对抗原免疫应答的活性物质,也是近年来研究的热点.免疫佐剂种类众多,利用细菌及其代谢产物作为黏膜免疫佐剂具有很好的发展前景,研究较多的是霍乱毒素(CT)和大肠埃希菌不耐热肠毒素(LT),从研究效果看,LT比CT更为理想.但是LT和CT一样本身具有毒性,这是其作为黏膜佐剂的主要缺点.目前,国内外研究工作者对其突变体做了大量研究,以期找到具有黏膜佐剂活性但低毒或无毒的大肠埃希菌不耐热肠毒素突变体.文章对大肠埃希菌不耐热肠毒素分子及其突变体的研究做一综述.